Loading
A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by Genentech, Inc., active and no longer recruiting.
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period is a phase 2 interventional study registered as NCT06524375 by Genentech, Inc., with 118 participants enrolled, started 2024-08-09 and due to reach its primary completion in 2026-10-31. Interventions recorded: Venetoclax and cBTKi Monotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/